NCT05092451View on ClinicalTrials.gov

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions

B-Cell LymphomaMyelodysplastic Syndromes (MDS)Acute Myeloid Leukemia (AML)Multiple MyelomaPlasma Cell LeukemiaHodgkin LymphomaT-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic LeukmeiaMyelodysplastic Syndrome / Chronic Myelomonocytic LeukemiaBlastic Transformation of Chronic Myeloid LeukemiaGerm Cell Tumors

Interventions

DRUG

Cyclophosphamide

Given by IV

DRUG

CAR.70/IL15-transduced CB-NK cells

Given by IV

DRUG

Fludarabine phosphate

Given by IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER